Pharmacokinetics of prothionamide in patients with multidrug-resistant tuberculosis

H. W. Lee, D. W. Kim, J. H. Park, S. D. Kim, M. S. Lim, P. B. Phapale, E. H. Kim, S. K. Park, Young Ran Yoon

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Abstract

SETTING: National Masan Tuberculosis Hospital, Masan, South Korea. OBJECTIVE: To evaluate the pharmacokinetics of prothionamide (PTH) in South Korean patients with multidrug-resistant tuberculosis (MDR-TB) and to investigate whether differences in body mass index (BMI) could explain observed differences in PTH disposition. DESIGN: Seventeen patients participated in the study; all had MDR-TB and had received combination anti-tuberculosis treatment, including PTH, cycloserine, ofloxacin, para-aminosalicylic acid and streptomycin or kanamycin, for at least 2 weeks. The patients were divided into two groups based on BMI: Group A (18.5 ≤S BMI < 23), and Group B (BMI < 18.5). Serum samples were collected over 24 h, and the plasma PTH concentration was determined by a validated high-performance liquid chromatography assay. RESULTS: After steady-state administration of PTH, the mean area under the plasma concentration-time curve from time 0 to 12 h (AUC0-12h) was 11.0 ± 3.7 μg h/ml. The mean Tmax and t1/2 were respectively 3.6 h and 2.7 h. No significant difference in PTH disposition was observed between groups A and B, except for ke and t1/2. CONCLUSION: In the pharmacokinetic parameter estimates for PTH in MDR-TB patients during routine treatment, the pharmacokinetics of PTH did not appear to correlate with extent of emaciation in MDR-TB patients.

Original languageEnglish
Pages (from-to)1161-1166
Number of pages6
JournalInternational Journal of Tuberculosis and Lung Disease
Volume13
Issue number9
StatePublished - Sep 2009

Keywords

  • MDR-TB
  • Pharmaco-kinetics
  • Prothionamide

Fingerprint

Dive into the research topics of 'Pharmacokinetics of prothionamide in patients with multidrug-resistant tuberculosis'. Together they form a unique fingerprint.

Cite this